SCHEMBL6929993

SCHEMBL6929993

CCc1ccc(C(=O)Nc2ccc(C(=O)CCC(=O)O)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
ATM Q13315 1/20 0.62
NR1H4 Q96RI1 5/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
RAB9A P51151 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 3/20 0.51
TRPV1 Q8NER1 2/20 0.51
F2 P00734 1/20 0.51
PLG P00747 1/20 0.51
PLAU P00749 1/20 0.51
PLAT P00750 1/20 0.51
KLKB1 P03952 1/20 0.51
PRSS1 P07477 1/20 0.51
PLK1 P53350 1/20 0.50
GAA P10253 1/20 0.50
PPARA Q07869 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5081078 0.86 L3MBTL1 (0.73) KMT2AMEN1ATML3MBTL1RAB9A
SCHEMBL6926264 0.85 KMT2A (0.72) KMT2AMEN1ATMNR1H4L3MBTL1
SCHEMBL6927758 0.84 NR4A2 (0.67) KMT2AMEN1NR1H4RAB9ASMN1; SMN2
SCHEMBL6927630 0.84 TRPV1 (0.64) NR1H4L3MBTL1TRPV1PLK1
SCHEMBL6931328 0.84 TRPV1 (0.64) NR1H4L3MBTL1TRPV1PLK1
SCHEMBL6926156 0.83 NR1H4 (0.52) NR1H4RAB9ASMN1; SMN2NPC1TRPV1
SCHEMBL6926157 0.83 NR1H4 (0.52) NR1H4RAB9ASMN1; SMN2NPC1TRPV1
SCHEMBL16607007 0.83 ALDH1A1 (0.69) KMT2AMEN1NR1H4RAB9ASMN1; SMN2
SCHEMBL6926215 0.82 NR1H4 (0.72) KMT2AMEN1NR1H4RAB9ASMN1; SMN2
SCHEMBL6925547 0.82 KMT2A (0.60) KMT2AMEN1NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US claimed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US claimed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US claimed
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US disclosed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US disclosed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases MMP1, MMP8, MMP13 KMT2A 4700/4885MEN1 3055/4885ATM 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.